Exhibit 1.01 Conflict Minerals Report of ResMed Inc.
For the Reporting Period from January 1, 2023 through
December 31, 2023
ResMed prepared
this conflict minerals report for the reporting period from January 1, 2023 through December 31, 2023 to comply with Exchange Act Rule 13p-1 (rule).
The rule requires ResMed to annually disclose information about the sources for tantalum, tin, tungsten, and gold (known as 3TG or conflict
minerals) that may be necessary to the manufacture or functionality of our products. This includes describing the due diligence we performed to determine the source and chain of custody of those minerals in our products, and whether they
originated from the Democratic Republic of the Congo or adjoining countries. The rule applies to 3TG. The rule refers to 3TG as conflict minerals regardless of where they are sourced and regardless of whether they benefit or finance
armed groups.
Part I. Company and Product Description
At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital
health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital
software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.
By enabling better
care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.
Part II. Reasonable Country of Origin Inquiry
ResMeds supply chain consists of multiple tiers, as we purchase components or subassemblies from our suppliers, they purchase from their suppliers, and
so on. ResMed sources components from hundreds of tier one suppliers. We are several tiers removed from the smelters, refiners and mining companies performing 3TG extraction and initial processing. To determine which suppliers provide us with
components covered by the rule, we reviewed the product composition data of our products and examined whether our products contained 3TG that are necessary to their functionality or necessary to their production. For products that contained 3TG, or
that we determined may have contained 3TG, we conducted a reasonable country of origin inquiry, designed to determine whether any of the necessary 3TG in our products originated or may have originated in a country covered by the rule, or came from
recycled or scrap sources.
During calendar year 2023 ResMed continued a partnership with a third-party consultant and industry specialist to assist in
carrying out our conflict minerals program. We contacted in-scope suppliers to explain ResMeds use of a third-party consultant to act on our behalf, collecting and analyzing 3TG information. We believe
that working with an industry specialist allows for more efficient and accurate data gathering, provides an industry standard approach, and gives ResMed the ability to review supplier responses against an existing database of information.
We began our reasonable inquiry by contacting suppliers who sold us components or subassemblies that contained or that we determined may have contained
necessary 3TG. We offered our suppliers two options for submitting the required information, either by uploading the conflict minerals reporting template by the Responsible Minerals Initiative, or by submitting an online survey version of this
template directly to our third-party consultant. Our calendar year 2023 response rate on applicable sourced parts is 94% with 89% of suppliers in scope responding.
Based on a review of our products and our reasonable inquiry, we have concluded in good faith that certain products of ours contain one or more 3TG that are
necessary to their functionality or production. We elected to conduct due diligence on the source and chain of custody of the necessary 3TG in our products.
1